Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine

Anne-Maree Kelly, Michael Ardagh, Chris Curry, Jenny D’Antonio, Steven Zebic

Abstract

**Objective**—To establish whether there is any difference in the efficacy of a chlorpromazine regimen and a sumatriptan regimen for the management of the pain of acute severe migraine.

**Setting**—Two urban teaching hospital emergency departments.

**Methods**—Prospective, randomised, unblinded, crossover trial. All patients received intravenous metoclopramide 10 mg and 1000 ml of normal saline over 1 h; 20 were then randomised to receive intramuscular sumatriptan 6 mg and 23 to receive intravenous chlorpromazine, 12.5 mg increments to a maximum of 37.5 mg. Response to treatment was measured using visual analogue pain scales.

**Results**—No difference in efficacy between the sumatriptan regimen and the chlorpromazine regimen was found. Adverse effects were mild and equally distributed between the groups.

**Conclusions**—The chlorpromazine and sumatriptan regimens studied are both very effective for the relief of the headache of severe migraine.

(J Accid Emerg Med 1997;14:209–211)

Keywords: migraine treatment; chlorpromazine; sumatriptan

Patients with severe migraine present to emergency departments infrequently but pose a considerable management dilemma. The pathophysiology of migraine is still not well understood and various treatments are used. These include narcotic analgesics, metoclopramide, dicyclomine, oral and parenteral non-steroidal anti-inflammatory agents, chlorpromazine, and sumatriptan. A review of published reports suggests that the two most effective agents (with respect to relief of pain and frequency of rebound headache) are intravenous chlorpromazine and intramuscular or subcutaneous sumatriptan.

Current research suggests that the headache pain of migraine results from the activation of the trigeminovascular system. The trigeminal system and when stimulated produces constriction of large blood vessels which may be dilated during attacks of migraine. Clinical response begins within 10–15 minutes of subcutaneous injection. Adverse effects include drowsiness, weakness, dizziness, flushing, rash, pruritus, increase in blood pressure, chest pain, and chest tightness. Sumatriptan is contraindicated in patients with a history of ischaemic heart disease and uncontrolled hypertension and in those using ergot preparations. The anti-migraine effect of sumatriptan is thought to be due to its effect on the 5-HT subtype 1D receptors in cranial blood vessels. The reported success rate of sumatriptan regimens varies from 47% to 96%.

Sumatriptan is a specific and selective 5-HT (subtype 1D) agonist that has no effect on other 5-HT receptor subtypes. This receptor is found predominantly in cranial blood vessels and when stimulated produces constriction of large blood vessels which may be dilated during attacks of migraine. Clinical response begins within 10–15 minutes of subcutaneous injection. Adverse effects include drowsiness, weakness, dizziness, flushing, rash, pruritus, increase in blood pressure, chest pain, and chest tightness. Sumatriptan is contraindicated in patients with a history of ischaemic heart disease and uncontrolled hypertension and in those using ergot preparations. The anti-migraine effect of sumatriptan is thought to be due to its effect on the 5-HT subtype 1D receptors in cranial blood vessels. The reported success rate of sumatriptan regimens varies from 47% to 96%.

There is a considerable cost difference between these agents, with an ampoule of chlorpromazine costing Australian hospital pharmacies $0.71, compared with $47.31 for an ampoule of sumatriptan.
As these agents have not previously been compared in a prospective clinical trial, this study was designed to establish whether there is any difference in the efficacy of a chlorpromazine regimen and a sumatriptan regimen for managing the pain of acute severe migraine.

Methods
This study was conducted as a randomised, prospective, unblinded crossover trial. Subjects were enrolled from the emergency departments of Western Hospital Footscray, Melbourne, Australia and Christchurch Hospital, Christchurch, New Zealand. Approval of the ethics committees of both institutions was obtained.

The inclusion criteria were: age 18–65 years, features typical of migraine, past history of migraine headache, and no impairment of conscious state. Exclusion criteria were: headache not typical of migraine, allergy to any of the study agents, inability to mark a visual analogue pain scale, the presence of abnormal neurological signs, failure to give informed consent, and impairment of conscious state.

All patients, after giving informed consent, were asked to indicate the level of their pain on a 10 cm non-hatched visual analogue pain scale, marked from "0" at one end to "10" at the other. Patients were verbally instructed that "0" meant "no pain" and "10" meant "worst pain ever".

Each then received metoclopramide 10 mg intravenously and an infusion of normal saline was started, 1000 ml to be given over one hour. The normal saline infusion was used to counter the dehydration which is commonly associated with severe migraine. Metoclopramide was given for its anti-nausea effects. The researchers were aware that metoclopramide might of itself have an impact on migraine, with reported success rates for its use of 0–60% (mean value approximately 40%). As this was consistently much lower than the reported success rates of either sumatriptan or chlorpromazine in previous studies, we chose not to include a separate metoclopramide-alone arm for ethical reasons.

Patients were then randomised by date of presentation to receive either chlorpromazine 12.5 mg intravenously, repeated at 25 minutes and 45 minutes if needed, or sumatriptan 6 mg intramuscularly. This was given within five minutes of the metoclopramide. On odd dates patients received the sumatriptan regimen and on even dates the chlorpromazine regimen. The study design determined that if, two hours after administration of the trial drug, pain was still rated at more than 30% of the length of the visual analogue scale, the patient was to be crossed over to the other agent.

Pain was measured using the visual analogue scale at enrolment and one and two hours after administration of the trial drug. The study definition of treatment success was relief of pain to the patient's satisfaction. If pain was controlled to the patient's satisfaction two hours after last medication, they were discharged home. If not, they were withdrawn from the study for further investigation and management. The occurrence of adverse events was recorded.

Results
Forty three patients were enrolled in the study, 20 in the sumatriptan group and 23 in the chlorpromazine group. The age and gender distribution in the groups is shown in table 1.

Mean pain scores at enrolment and at one hour and two hours after treatment are shown in table 2. The data were analysed using analysis of variance. The hypothesis that there was no difference in efficacy between the regimens was accepted at the 0.05 level of significance.

The close similarity in efficacy is also shown by the proportion of patients in each group who were pain-free (that is, VAS score = 0) at each time interval. Ten per cent of the patients in the sumatriptan group were pain-free at one hour compared to 18% of the chlorpromazine group. Forty two per cent of the sumatriptan group were pain-free at two hours, compared to 41% of the chlorpromazine group. Relief of pain to the patient's satisfaction with the sumatriptan regimen occurred in 19/20 (95%) and with the chlorpromazine regimen in 22/23 (95%). Only one patient from each group failed to achieve analgesia to their satisfaction. One of these was crossed over to the other arm of the study and following treatment with the alternative drug continued to report moderate headache. The other patient declined further treatment.

Six occurrences of adverse events were reported: three in the sumatriptan group and three in the chlorpromazine group. All were mild, did not require specific treatment, and resolved within the study period. In the sumatriptan group the adverse symptoms reported were nausea (1), burning in the face (1), and unpleasant dreams (1). In the chlorpromazine group the events were dizziness (1), fever (1), and one transient episode of palpitations (sinus tachycardia). The patient who experienced transient fever had a normal CSF examination and white cell count. No infective focus was identified. Of particular note, no episode of a dystonic reaction occurred in either group.

Discussion
Migraine headache can be a disabling condition. Most migraine headaches are successfully managed by the patient and their general practitioner; however, a few fail to respond and present to emergency departments. As most patients have tried oral medications before attending, parenterally administered agents are most appropriate for use in emergency departments. A recent review of published reports suggests that the two most effective agents (with respect to relief of pain and incidence of
been suffering their migraine for some hours before presentation and have also been vomiting, resulting in a degree of dehydration. The chlorpromazine regimen does include some fluid replacement which may be of independent benefit. Given the similarity in efficacy of these agents, the choice of agent will therefore depend on considerations of cost, convenience, and the management of dehydration.

CONCLUSION
Both the sumatriptan and chlorpromazine regimens studied are highly effective for the treatment of the pain of migraine. The chlorpromazine regimen studied is as effective as the sumatriptan regimen for the relief of the headache of severe migraine and at a lower cost.

12 Buzzi MG, Moskowitz MA. Evidence for 5-HT{sub 1B/1D} receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991;11:105-8.